Correlation between early subjective response to antipsychotics and the number of hospitalizations and hospitalization days in a period of 10-11 years in schizophrenia patients

Neuropsychobiology

Volumn 66, Issue 2, 2012, Pages 120-125

  Murawiec, Slawomir ^a   Boutros, Nash N ^b  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Prognosis; Schizophrenia; Subjective response

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; PERAZINE; PERPHENAZINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ATTITUDE INVENTORY 10 QUESTIONNAIRE; EARLY SUBJECTIVE RESPONSE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; SCHIZOPHRENIA; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; QUESTIONNAIRES; SCHIZOPHRENIA; SELF REPORT; TREATMENT OUTCOME;

EID: 84863880829     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000339092     Document Type: Article

References (15)

1. Awad AG: Neuroleptic dysphoria: revisiting the concept 50 years later. Acta Psychiatr Scand 2005; 111(suppl 427):6-13. (Pubitemid 40780194)
2. Van Putten T, May PRA: Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978; 35: 477-480. (Pubitemid 8337039)
3. Van Putten T, May PRA, Marder SR, Whittman LA: Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38: 187-190. (Pubitemid 11142771)
4. Awad AG: Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders. Expert Rev Pharmacoecon Outcome Res 2010; 10: 1-4.
5. Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad AG: Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43: 135-145. (Pubitemid 30386882)
6. Hogan TP, Awad AG, Eastwood R: A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13: 177-183. (Pubitemid 13132147)
7. Awad AG, Hogan TP: Early treatment events and prediction of response to neuroleptics in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1985; 9: 585-588. (Pubitemid 16148263)
8. Hogan TP, Awad AG: Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992; 22: 347-352.
9. Rossi A, Pacifico R, Stratta P: Attitudes toward medication and the clinical variables in schizophrenia: structural equation models. Patient Prefer Adherence 2009; 3: 305-309.
10. Kuroda N, Sun S, Lin CK, Morita N, Kashiwase H, Yang F, Nakatani Y: Attitudes toward taking medication among outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing. Environ Health Prev Med 2008; 13: 288-295.
11. Patel MX, De Zoysa N, Bernadt M, David A: Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 2009; 23: 789-796.
12. Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker WW: Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002; 63: 49-53. (Pubitemid 34113487)
13. Hofer A, Rettenbacher MA, Edlinger M, Kemmler G, Widschwendter CG, Fleischhacker WW: Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia. Acta Psychiatr Scand 2007; 116: 354-361. (Pubitemid 47537427)
14. Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, Awad AG: Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D 2 binding ratios on SPECT imaging. Neuropsychopharmacol 2001; 25: 642-650. (Pubitemid 32995946)
15. Voruganti L, Awad AG: Subjective and behavioral consequences of striatal dopamine depletion in schizophrenia-findings from an in vivo SPECT study. Schizophr Res 2006; 88: 179-186. (Pubitemid 44693241)